SEOM—GECOD clinical guideline for unknown primary cancer (2021)

• Ferrán Losa ^[6] ; Isaura Fernández ^[7] ; Olatz Etxaniz ^[8] ; Alejandra Giménez ^[9] ; Paula Gomila ^[1] ; Lara Iglesias ^[2] ; Federico Longo ^[3] ; Esteban Nogales ^[4] ; Antonio Sánchez ^[5] ; Gemma Soler ^[10]
  1. [1] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  2. [2] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  3. [3] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  4. [4] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  5. [5] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  6. [6] Hospital de Sant Joan Despí Moisés Broggi-ICO Hospitalet, Barcelona, Spain
  7. [7] Hospital Álvaro Cunqueiro-IIGS, Vigo, Spain
  8. [8] Hospital Germans Trias I Pujol -ICO Badalona, Barcelona, Spain
  9. [9] Hospital Lluís Alcanys de Xàtiva, Valencia, Spain
  10. [10] Hospital Durán i Reynals-ICO Hospitalet, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 681-692
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It is considered a separate entity with a specific biology, and nowadays molecular characteristics and the determination of actionable mutations may be important in a significant group of patients. In this guide, we summarize the diagnostic, therapeutic, and possible new developments in molecular medicine that may help us in the management of this unique disease entity.